Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Armodafinil in Excessive Sleepiness
NCT00078312Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of armodafinil in narcolepsy, obstructive sleep apnea syndrome (OSAS) and shift work sleep disorder (SWSD), sponsored by Cephalon, Inc. Primary endpoint: Safety and Tolerability as Measured by Number of Participants With Adverse Events at 12 months. Started Jan 2004; status: completed.
02
Drugs
armodafinil
03
Conditions
narcolepsyobstructive sleep apnea syndrome (OSAS)shift work sleep disorder (SWSD)
Beyond the preview
Go deeper on NCT00078312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078312.